Shattuck Labs (NASDAQ:STTK) Issues Earnings Results

Shattuck Labs (NASDAQ:STTK) announced its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04), FiscalAI reports.

Shattuck Labs Trading Down 12.8%

Shattuck Labs stock traded down $0.66 during mid-day trading on Thursday, reaching $4.49. The company’s stock had a trading volume of 1,434,725 shares, compared to its average volume of 1,030,330. The firm has a market cap of $450.63 million, a price-to-earnings ratio of -8.80 and a beta of 1.21. The business has a 50 day moving average price of $6.06 and a 200-day moving average price of $6.02. Shattuck Labs has a twelve month low of $1.72 and a twelve month high of $8.33.

Analysts Set New Price Targets

STTK has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research report on Friday, September 11th. Wall Street Zen downgraded Shattuck Labs from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. Leerink Partners started coverage on Shattuck Labs in a report on Monday, July 20th. They issued an “outperform” rating and a $16.00 price objective for the company. Wedbush boosted their price objective on Shattuck Labs from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, October 2nd. Finally, HC Wainwright cut their price objective on Shattuck Labs from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $13.70.

About Shattuck Labs

Shattuck Labs, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1.